Trial Profile
BGOG-cx1/ENGOT-cx1: Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Mar 2022 Planned End Date changed from 1 Jul 2023 to 1 Oct 2023.
- 08 Jul 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Sep 2020.
- 09 Jul 2019 Planned End Date changed from 1 Jul 2020 to 1 Jul 2023.